



CARDIOVASCULAR

Cardiovascular Trials: the Julius Clinical Solution

Julius Clinical manages global clinical drug trials that will have a major impact on medicine and make a real difference to people's lives around the world.

Our unique combination of scientific leadership and operational excellence ensures that the trial data is of the highest quality. Our internationally recognised academic leaders are actively involved in the design, conduct, and interpretation of clinical trials. This scientific expertise and credibility combined with operational excellence means that we are uniquely equipped to assist in providing answers for today's clinical drug development challenges.

Cardiovascular disease is a major burden worldwide. It has been estimated that deaths due to heart disease will increase by 50% in developed countries and by 100% in low and middle income countries by 2020. However, there has been a decline in all phases of cardiovascular drug development in the past decade. This can be attributed to several factors: increased regulatory demands for more and more data; patient recruitment; complexity of protocols; and studies are long and costly – especially if the results do not result in any new treatments or have a negative impact on the subjects. It is clear, therefore, a new way of conducting trials in a cost-effective and more streamlined manner needs to be found.

CARDIOVASCULAR

The Challenges:

- Large number of subjects needed and target population is decreasing due stringent inclusion / exclusion requirements
- Trials are complex and costly – it can take 10 years and an investment of \$4 Billion to bring one new novel drug to market
- Regulatory agencies are demanding more and more data, with an emphasis on clinical outcome, which increases the complexity of the protocols

Our Solution:

- Global scientific networks and peer-to-peer leadership model greatly increase recruitment of the right subjects at the right locations
- Operational excellence ensures faster start-up and trial management
- Deep in-house Cardiovascular expertise and access to academic institutions that aid in protocol development
- Comprehensive understanding of the regulatory environment

TRACK RECORD (a selection) | CARDIOVASCULAR

STUDY	PERIOD	JC PATIENTS	THERAPEUTIC AREA
SPIRE	2014 - 2017	6,729	Cardiovascular Diseases
Reshape	Ongoing	Ongoing	Heart Failure
METEOR	Ongoing	Ongoing	Measuring Effects on intima media Thickness
Alecardio	2009 - 2013	5,760	Acute Coronary Syndrome
Remote-CIED	Ongoing	Ongoing	Congestive Heart Failure



John J.P. Kastelein is Professor of Medicine at the Department of Vascular Medicine at the Academic Medical Center (AMC) of the University of Amsterdam, where he holds the Strategic Chair of Genetics of Cardiovascular Disease. Professor Kastelein is also one of our Associated Scientists.



Broederplein 41-43
3703 CD Zeist
The Netherlands

+31 (0)30 656 99 00
info@juliusclinical.com
www.juliusclinical.com